SCHEMBL3296992

SCHEMBL3296992

COc1c(C(N)=O)cc(-c2ccccc2)c(F)c1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.54
BCAT2 O15382 1/20 0.45
HTT P42858 1/20 0.43
CHUK O15111 4/20 0.43
IKBKE Q14164 1/20 0.43
PKMYT1 Q99640 1/20 0.43
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
TUBB4A P04350 4/20 0.40
TUBB P07437 4/20 0.40
TUBA3C P0DPH7 4/20 0.40
TUBA1B P68363 4/20 0.40
TUBA4A P68366 4/20 0.40
TUBB4B P68371 4/20 0.40
TUBB3 Q13509 4/20 0.40
TUBB2A Q13885 4/20 0.40
TUBB8 Q3ZCM7 4/20 0.40
TUBA3E Q6PEY2 4/20 0.40
TUBA1A Q71U36 4/20 0.40
TUBA1C Q9BQE3 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3294545 0.90 HTT (0.44) IKBKBHTTALOX5APFEN1TUBB4A
SCHEMBL3298185 0.88 GABRA1 (0.47) IKBKBHTT
SCHEMBL18816717 0.81 IKBKB (0.58) IKBKBBCAT2HTTCHUKIKBKE
SCHEMBL18816697 0.78 IKBKB (0.54) IKBKBBCAT2HTTTUBB4ATUBB
SCHEMBL9951887 0.76 BCAT2 (0.53) IKBKBBCAT2CHUKIKBKEPKMYT1
SCHEMBL28789773 0.75 IKBKB (0.65) IKBKBBCAT2HTTTUBB4ATUBB
SCHEMBL18816703 0.75 IKBKB (0.48) IKBKBBCAT2HTTPDE4BBRD4
SCHEMBL18641956 0.74 IKBKB (0.52) IKBKBBCAT2HTTTUBB4ATUBB
SCHEMBL3295542 0.73 MAOA (0.46) ALOX5APFEN1
SCHEMBL30504310 0.73 BCAT2 (0.62) IKBKBBCAT2HTTPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737166-B2 Antifungal bicyclic hetero ring compounds DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-06-15 US disclosed
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-06-04 US disclosed
EP-1932837-A1 BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION Daiichi Sankyo Company, Limited (JP) 2008-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143353-A1 such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides CTPS1, TPP1, STS IKBKB 1633/4885BCAT2 602/4885HTT 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.